title: Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis.
abstract: OBJECTIVE
  In this study, we investigated the efficacy of systemic and intravitreal (IV) infliximab treatments and compared these 2 different treatment modalities in an experimental model of endotoxin-induced uveitis (EIU).
  
  
  METHODS
  Twenty-four white New Zealand rabbits were equally divided into 4 groups. Group 1 received IV injection of lipopolysaccharide (LPS), group 2 received IV injections of LPS and saline, group 3 received IV LPS and IV 2 mg/0.1 cc infliximab, and group 4 received IV LPS and 5 mg/kg intravenous infliximab. Inflammation was determined with objective and subjective tests. The subjective test was clinical determination of uveitis, the objective tests were determination of protein concentrations and tumor necrosis factor alpha (TNF-α) levels and histopathology.
  
  
  RESULTS
  Clinical examination score was lower in group 3 and group 4 (4±0.6 and 3.5±1.6, respectively) when compared with group 1 (P=0.02; P=0.04, respectively) and group 2. In group 3 and 4, the aqueous and vitreous protein and TNF-α concentration measured significantly lower than group 1 and 2. In histopathologic examination, there was no statistically significant difference between group 1, 2, and 3 (3.5±0.5, 3.6±0.5, 3.6±0.5, respectively). However, the lowest histopathologic inflammation was determined in group 4 (2.5±0.5) (compared with group 1 and group 3, respectively; P=0.03; P=0.014).
  
  
  CONCLUSIONS
  In a rabbit model of experimental EIU, intravenous administration of infliximab was more effective than IV route in an acute period.
authors.affiliation: 1 Kahramanmaras Necip Fazıl City Hospital , Kahramanmaras, Türkiye.
authors.forename: Erdem
authors.initials: E
authors.lastname: Yuksel
authors.forename: Berati
authors.initials: B
authors.lastname: Hasanreisoglu
authors.forename: Nilay
authors.initials: N
authors.lastname: Yuksel
authors.forename: Guldal
authors.initials: G
authors.lastname: Yilmaz
authors.forename: Ugur
authors.initials: U
authors.lastname: Ercin
authors.forename: Ayse
authors.initials: A
authors.lastname: Bilgihan
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000378:metabolism; D000069285:Infliximab; D007275:Injections, Intravenous; D058449:Intravitreal Injections; D008070:Lipopolysaccharides / Q000633:toxicity; D011817:Rabbits; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D014605:Uveitis / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005136:Eye Proteins; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab